Abstract
To determine whether the mast cell (MCs) and tumor-associated macrophage (TAMs) counts have any correlation with clinical outcome in colorectal cancer, and to investigate whether MCs undergo phenotypic changes in colorectal cancer. The MC and TAM counts were determined immunohistochemically in 60 patients with colorectal cancer and the depth of invasion, lymph node metastasis rate, distant metastasis rates, and survival rates were compared between patients with low (less than the mean number of positive cells) and high (more than the mean number of positive cells) cell counts. Both patients with a low MC count and patients with a low TAM count had significantly deeper depth of invasion than those with a high MC count and those with a high TAM count (P<0.01 and P<0.01 respectively). Patients with a high MC count and patients with a high TAM count were significantly higher showing significantly lower rates of lymph node metastasis, distant metastasis than those with a low MC count and those with a low TAM count. There were significant positive correlation between MC counts and TAM counts (r = 0.852, P<0.01). In both cancerous tissue and normal colorectal tissue, the predominant MC phenotype was MC(TC). The 5-year survival rate estimated was significantly lower in both patients with a low MC count and patients with a low TAM count than in those with a high MC count and those with a high TAM count (P<0.05 and P<0.01 respectively). There appears to be a direct relationship between the number of MCs and clinical outcome in patients with colorectal cancer, even though MCs exhibited no significant phenotypic changes. TAM count is of value to predict the clinical outcome or prognosis. It is more beneficial for estimating biological character of colorectal carcinoma to combine MC and TAM counts.
MeSH Terms
Aged
Aged, 80 and over
Antigens/metabolism
Cell Count
Chymases
Colorectal Neoplasms/immunology,mortality,secondary
Female
Humans
Immunohistochemistry
Immunologic Surveillance
Lymphatic Metastasis
Macrophages/cytology,immunology
Male
Mast Cells/cytology,immunology
Middle Aged
Phenotype
Prognosis
Serine Endopeptidases/metabolism
Survival Analysis
Tryptases
Chemicals
Antigens
Serine Endopeptidases
Chymases
Tryptases
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Tan Shi-Yun
Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China. tanshiyun@medmail.com.cn
Fan Yan
Luo He-Sheng
Shen Zhi-Xiang
Guo Yi
Zhao Liang-Jia
References (26)
26 references, click to expand
-
The origin and function of tumor-associated macrophages.
Immunol Today. 1992 Jul;13(7):265-70
PMID: 1388654
-
Fibrosarcoma-induced increase in macrophage tumor necrosis factor alpha synthesis suppresses T cell responses.
J Leukoc Biol. 1993 Aug;54(2):152-60
PMID: 8360594
-
Phenotypic changes in mast cells proliferating in the rat lung following infection with Nippostrongylus brasiliensis.
Virchows Arch B Cell Pathol Incl Mol Pathol. 1987;54(1):1-7
PMID: 2892299
-
Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
J Hepatol. 2000 Dec;33(6):961-6
PMID: 11131459
-
Mouse mast cells as anti-tumor effector cells.
Cell Immunol. 1980 Oct;55(2):294-301
PMID: 7428049
-
Protease-induced leukocyte chemotaxis and activation: roles in host defense and inflammation.
J Med Invest. 2001 Aug;48(3-4):133-41
PMID: 11694952
-
Mast cells and tumors. The specific enhancement of tumor proliferation in vitro.
Am J Pathol. 1985 Apr;119(1):57-64
PMID: 3985123
-
Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma.
Am J Pathol. 1995 Sep;147(3):564-73
PMID: 7545872
-
Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor.
J Clin Invest. 1997 Jun 1;99(11):2691-700
PMID: 9169499
-
Histochemical heterogeneity of human mast cells: disease-related differences in mast cell subsets recovered by bronchoalveolar lavage.
Int Arch Allergy Appl Immunol. 1990;92(3):233-41
PMID: 1703515
-
The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a potent stimulant of mast cells.
Eur J Immunol. 2002 Mar;32(3):671-6
PMID: 11857341
-
Mast cells and human hepatocellular carcinoma.
World J Gastroenterol. 2003 Jul;9(7):1469-73
PMID: 12854143
-
Mast cell-mediated tumor-cell cytotoxicity. Role of the peroxidase system.
J Exp Med. 1981 Mar 1;153(3):520-33
PMID: 7252407
-
Prognostic value of tumor-associated macrophage count in human bladder cancer.
Int J Urol. 2000 Jul;7(7):263-9
PMID: 10910229
-
Mast cells in breast cancer.
Anticancer Res. 1993 May-Jun;13(3):785-8
PMID: 8317912
-
Mast cell subpopulations in chronic inflammatory hepatobiliary diseases.
Liver. 2000 Apr;20(2):152-6
PMID: 10847484
-
Inflammatory cells and cancer: think different!
J Exp Med. 2001 Mar 19;193(6):F23-6
PMID: 11257144
-
Two types of human mast cells that have distinct neutral protease compositions.
Proc Natl Acad Sci U S A. 1986 Jun;83(12):4464-8
PMID: 3520574
-
Chymase-positive mast cells in small sized adenocarcinoma of the lung.
Virchows Arch. 2003 Oct;443(4):565-73
PMID: 12827514
-
Mast cells and angiogenesis.
APMIS. 2002 May;110(5):355-71
PMID: 12076253
-
Human mast cell chymase induces the accumulation of neutrophils, eosinophils and other inflammatory cells in vivo.
Br J Pharmacol. 1998 Dec;125(7):1491-500
PMID: 9884078
-
In vitro generated mast cells express natural cytotoxicity against tumour cells.
Immunology. 1985 Jun;55(2):317-24
PMID: 3924820
-
Mast cells and angiogenesis.
Semin Cancer Biol. 1992 Apr;3(2):73-9
PMID: 1378312
-
Correlation between mast cells and survival rates in patients with pulmonary adenocarcinoma.
Lung Cancer. 1999 Nov;26(2):103-8
PMID: 10568681
-
Mast cell granules cause proliferation of human microvascular endothelial cells.
Lab Invest. 1986 Sep;55(3):289-94
PMID: 2427796
-
Mast cell-tumor cell interactions: for or against tumour growth and metastasis?
Anticancer Res. 1997 May-Jun;17(3A):1541-9
PMID: 9179193